Article info

Original research
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

Authors

  1. Correspondence to Dr Saisha A Nalawade; saisha.nalawade{at}bcm.edu
View Full Text

Citation

Nalawade SA, Shafer P, Bajgain P, et al
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

Publication history

  • Accepted October 14, 2021
  • First published November 23, 2021.
Online issue publication 
November 23, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.